
	Prothena is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel antibodies that are directed towards diseases that involve protein misfolding or cell adhesion.
	
	The Company&rsquo;s work in protein misfolding could result in therapies to treat a number of diseases, including AL (primary) and AA (secondary) forms of amyloidosis (NEOD001), and Parkinson&rsquo;s disease and other related synucleinopathies (PRX002). Prothena&rsquo;s novel cell adhesion development activities could generate new therapies to treat inflammatory diseases and cancers (PRX003). Our strategy is to identify antibody candidates for clinical development by applying Prothena&rsquo;s extensive expertise in generating novel therapeutic antibodies and working with collaborators having expertise in specific animal models of disease. Our lead programs, NEOD001 and PRX002, are in Phase 1 clinical trials, and we anticipate moving PRX003 into clinical development in 2015.
	
	Prothena has attracted an elite team with a recognized track record both for profound scientific discoveries and for the development of therapeutics that have become leading commercial products in their respective therapeutic categories. The team brings this heritage to Prothena with the vision of continuing to create and develop novel antibody-based therapies that benefit patients with diseases caused by protein misfolding or cell adhesion. We also have assembled a globally recognized Scientific Advisory Board with a broad spectrum of academic and industry experience in the fields of neuroscience and immunotherapy.
	
	Prior to December 2012, the Prothena Business operated as part of Elan Corporation, plc (Elan), and not as a separate stand-alone entity. Prothena&rsquo;s business consists of a substantial portion of Elan&rsquo;s former drug discovery business platform, including Neotope Biosciences Limited and Onclave Therapeutics Limited, each former wholly owned subsidiaries of Elan. After the separation from Elan and the related distribution of our ordinary shares to Elan&rsquo;s stockholders, our ordinary shares began trading on The NASDAQ Global Market under the symbol &ldquo;PRTA&rdquo; on December 21, 2012.
